Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia Completes Acquisition of Oxford s Software Subsidiaries

NEW YORK, Sept 6 - Pharmacopeia (Nasdaq: PCOP) said Wednesday it had completed the acquisition of the software subsidiaries of Oxford Molecular Group of Oxford, UK.

The deal, which was valued at about $27 million, including cash and the assumption of certain liabilities, includes Oxford’s GCG bioinformatics software line and its RS3 cheminformatics products.

“The scientific products and technologies that we have acquired from Oxford Molecular will enhance and complement our existing drug discovery and chemical development solutions,” Joseph Mollica, Pharmacopeia’s chairman, president and CEO, said in a statement.

Pharmacopeia of Princeton, NJ develops tools and methods for accelerating drug discovery and chemical development. Its software operation includes MSI and Synopsys Scientific Systems. The company employs about 675 people and had revenues of $104 million in 1999.

The acquisition ends speculation about the fate of the beleaguered Oxford Molecular Group. The company had been racked with financial losses and had been criticized for not leveraging GCG’s product line after buying the company for $20 million in 1998.

Oxford Molecular plans to sell its remain assets and disband.


The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more